Best Paper Award

Dear Colleagues,

We are pleased to announce the “JPM 2022 Best Paper Award” for research and review articles published in JPM from 1 January 2022 to 31 December 2022. One review and one research article will receive an award each. The papers will be selected after a thorough evaluation by the journal Award Committee led by the Editor-in-Chief, Prof. Dr. David Alan Rizzieri.

Eligibility for the Award:
– Papers published in JPM from 1 January 2022 to 31 December 2022;
– Open to all career levels;
– Both regular and Special Issue submissions will be considered.

Selection Criteria:
The papers will be selected by the journal Award Committee according to the following criteria:
– Scientific merit and broad impact;
– Originality of the research objectives and/or the ideas presented;
– Creativity of the study design or uniqueness of the approaches and concepts;
– Clarity of presentation;
– Citations and downloads.

The Prize:
– One review award: CHF 500 and a chance to publish a paper free of charge in JPM before 30 December 2025 after peer review;
– One research article award: CHF 500 and a chance to publish a paper free of charge in JPM before 30 December 2025 after peer review;
– Each winner will also receive a certificate.

The winners will be announced on the journal website on 31 July 2024.

Kind regards,
JPM Editorial Office

 
JPM 2022 Best Paper Award
 
Winner announcement: 31 July 2024
 
Past Winners
 
Year: 

Winner

Francine Durocher
1. Department of Molecular Medicine, Faculty of Medicine, Université Laval, Quebec City, QC G1T 1C2, Canada 2. Cancer Research Center, CHU de Québec-Université Laval, Quebec City, QC G1V 4G2, Canada
Zhiqiang Kevin Lu
College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA

Winner

Molecular and Cellular Mechanisms Affected in ALS
Northern Ireland Center for Stratified/Personalised Medicine, Biomedical Sciences Research Institute, Ulster University, Derry-Londonderry BT47, UK
Postulated Adjuvant Therapeutic Strategies for COVID-19
Fagron. Lichtenauerlaan 182, 3062 Rotterdam, The Netherlands
Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
CEINGE—Biotecnologie Avanzate s.c.a.r.l., 80131 Naples, Italy Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, 80131 Napoli, Italy Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pasca

Award Committee

Prof. Dr. Richard E Frye Chairman
Autism Discovery and Treatment Foundation
Back to TopTop